The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.
A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.
Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
Hair transplants and hair loss treatments like oral Fin and Min are discussed, with some humor about public figures' hair. Missing a single day of these treatments typically has little impact, but longer gaps can affect results.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
The post discusses a 10-year battle with hair loss using treatments like biotin, Rogaine, Dualgen 15% Minoxidil, dermaroller, and various skin care products. Despite some side effects, the user maintains a full head of hair and is considering a hair transplant in the future.
The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.
The user has tried various hair loss treatments, including minoxidil, finasteride, ketoconazole, biotin spray, oral medications, and a Revian cap, but has not seen lasting improvement. They are considering stopping treatments and are frustrated with the lack of progress and the financial and emotional toll.
The conversation is about a person's hair loss treatment regimen, which includes Minoxidil, low-dose Finasteride, Pyrilutamide, weekly use of a derma roller, and hair loss shampoo. They chose these treatments to minimize systemic effects and plan to share their results for others' benefit.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
A 22-year-old male has been using finasteride, topical minoxidil, and oral minoxidil for hair loss but sees minimal improvement and is considering adding dutasteride. Users suggest additional treatments like dermarolling, PRP, and consulting a dermatologist, or considering a hair transplant.
A 25-year-old male shared his 3-month progress using oral minoxidil, finasteride, and biotin for hair growth, reporting positive results and minimal side effects, such as slightly reduced libido. He plans to continue treatment and possibly add microneedling, with hopes of further improvement and potential hair transplant if needed.
A person improved hair loss from Norwood 3 to Norwood 2 using a topical formula with minoxidil, dutasteride, and tretinoin, plus oral minoxidil and red light therapy. There is skepticism about the treatment's effectiveness and concerns about misleading comparison photos.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
A user shared a natural hair loss treatment involving micro-needling and a mix of turmeric, cinnamon, and coconut oil, claiming it effectively thickened their hair. The treatment is applied every two to three weeks, but some users expressed skepticism and requested photographic evidence.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.